BTS Appointed Exclusive Global A2P SMS Aggregator for BBIX and SoftBank Corp.
20.1.2025 07:00:00 CET | Business Wire | Press release
Business Telecommunications Services, Inc. (BTS), a leading provider, technology enabler, and trusted partner to CommTech players, has today announced its appointment as the exclusive international A2P SMS aggregator for BBIX, Inc. (BBIX), a wholly-owned subsidiary and the official international A2P SMS gateway of SoftBank Corp. (SoftBank). This agreement marks a significant milestone in the five-year partnership between BTS, BBIX, and SoftBank, enabling seamless and innovative international communication solutions.
As the exclusive aggregator, BTS will be the official channel for terminating international A2P SMS traffic to the SoftBank network. This partnership mandates all communications providers to route their traffic destined for SoftBank through BTS, ensuring seamless and secure delivery. By leveraging the complementary strengths of each company, this partnership enhances the global messaging ecosystem with improved operational efficiencies, enabling a better customer experience and more responsive customer support.
BTS's extensive global footprint and BBIX's market expertise will help partners navigate complex regulatory environments, expand market reach, and unlock cross-selling opportunities that can drive higher revenue growth. The partnership also ensures the delivery of secure and reliable messaging services by leveraging BTS’s advanced S1 Platform.
“As a trusted partner, we are pleased to expand our collaboration with BTS to ensure the seamless aggregation of global A2P SMS traffic,” said Hideyuki Sasaki, President & CEO of BBIX. “By combining our strengths and complementary expertise, we are delivering a secure and reliable solution that enhances the SoftBank network and supports the evolving needs of our global partners.”
“As a trusted partner and joint venture collaborator, BTS has consistently demonstrated the capabilities and expertise we need to support SoftBank’s global communications strategy,” commented Norioki Sekiguchi, Vice President of SoftBank Corp.’s Global Business Division. “By leveraging BBIX as our official gateway, BTS will ensure the seamless and secure aggregation of international A2P SMS traffic to our network, enabling us to deliver greater reliability and performance for our customers worldwide.”
This agreement solidifies BTS’s leadership in the global messaging space and underscores the ongoing collaboration between BTS, BBIX, and SoftBank. Together, they continue to pioneer innovative and scalable solutions that address the dynamic needs of the global communications industry.
“Becoming the exclusive aggregator of A2P SMS for BBIX and SoftBank marks an important milestone in our partnership, which began over five years ago,” concluded Andrés Proaño, EVP & CRO of BTS. “This collaboration reflects the strength of our relationship and our shared commitment to driving innovation in global communications. With many more strategic initiatives ahead, such as Open Connectivity eXchange (OCX), Roaming Peering eXchange (RPX), and advanced AI solutions, this agreement is a key step forward in a partnership poised for even greater growth and success.”
About BTS
BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform and an international network of 400+ direct partners, BTS delivers advanced AI-driven solutions specializing in voice, messaging, cloud communications, and innovative services that drive growth for MNOs, carriers, digital players, and hyperscalers. BTS powers 18+ billion voice minutes annually across 180+ countries, with extensive cloud telephony coverage in 90+ hard-to-reach markets and global reach for messaging services.
About BBIX
BBIX was established in 2003 to be a carrier-free internet exchange (IX) provider headquartered in Japan and serving Asia, Europe, and the US. It provides various connectivity services such as IX, Roaming Peering eXchange (RPX), Open Connectivity eXchange (OCX), as well as A2P SMS solutions. BBIX has established itself as one of the leading IXs in Asia, with a growing membership and an expanding global footprint.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250119536400/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom